BMI与免疫检查点抑制剂治疗恶性肿瘤疗效的关系

doi:10.11904/j.issn.1002-3070.2022.02.016

摘要/Abstract

摘要： 近年来,免疫检查点抑制剂(Immune checkpoint inhibitors,ICIs)的问世彻底改变了多种恶性肿瘤的治疗格局。但是并非所有患者都能从免疫治疗中获益,免疫治疗的总体有效率偏低。因此,如何筛选免疫治疗获益人群就成为目前关注的热点问题。由于肿瘤的异质性、微环境复杂性、标本可及性等因素,目前用于指导肿瘤免疫治疗的生物标记物存在一定局限性。有研究探索了临床特征对免疫检查点抑制剂疗效的预测作用,其中包括体重指数(Body mass index,BMI)。本文就BMI与恶性肿瘤免疫治疗疗效的关系进行综述。

关键词: 恶性肿瘤, 体重指数, 免疫治疗, 免疫检查点抑制剂

Abstract: In recent years,immune checkpoint inhibitors(ICIs)have completely changed the treatment pattern of a variety of malignant tumors.However,not all patients can benefit from immunotherapy,and the overall effective rate is low.Therefore,how to screen the people who benefit from immunotherapy is currently a hot issue.Due to tumor heterogeneity,microenvironment complexity,specimen accessibility and other factors,the current biomarkers used to guide tumor immunotherapy have certain limitations.Studies have explored the predictive effect of clinical features on the efficacy of ICIs,including body mass index(BMI).This article reviews the relationship between BMI and the efficacy of immunotherapy for malignant tumors.

Key words: Malignant tumor, Body mass index, Immunotherapy, Immune checkpoint inhibitors

中图分类号:

R730.51

唐菊, 尚利华. BMI与免疫检查点抑制剂治疗恶性肿瘤疗效的关系[J]. 实用肿瘤学杂志, 2022, 36(2): 188-192.

TANG Ju, SHANG Lihua. The relationship between BMI and the efficacy of immune checkpoint inhibitors in the treatment of malignant tumors[J]. Journal of Practical Oncology, 2022, 36(2): 188-192.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.02.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I2/188

参考文献

1 Nosaki K,Saka H,Hosomi Y,et al.Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer:pooled analysis from the KEYNOTE-010,KEYNOTE-024,and KEYNOTE-042 studies[J].Lung Cancer,2019,135:188-195.
2 Ascierto PA,Del Vecchio M,Mandalá M,et al.Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma(CheckMate 238):4-year results from a multicentre,double-blind,randomised,controlled,phase 3 trial[J].Lancet Oncol,2020,21(11):1465-1477.
3 Motzer RJ,Tannir NM,Mcdermott DF,et al.Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma[J].N Engl J Med,2018,378(14):1277-1290.
4 Burtness B,Harrington KJ,Greil R,et al.Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-048):a randomised,open-label,phase 3 study[J].Lancet,2019,394(10212):1915-1928.
5 Gandhi L,Rodriguez-Abreu D,Gadgeel S,et al.Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J].N Engl J Med,2018,378(22):2078-2092.
6 Tay C,Qian Y,Sakaguchi S.Hyper-progressive disease:the potential role and consequences of T-regulatory cells foiling anti-PD-1 cancer immunotherapy[J].Cancers(Basel),2020,13(1):48.
7 Shen X,Zhao B.Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer:meta-analysis[J].BMJ,2018,362:3529.
8 Hellmann MD,Ciuleanu TE,Pluzanski A,et al.Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J].N Engl J Med,2018,378(22):2093-2104.
9 Khaddour K,Gomez-Perez SL,Jain N,et al.Obesity,sarcopenia,and outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors[J].Front Oncol,2020,10:576314.
10 Dimitrakopoulos FI,Nikolakopoulos A,Kottorou A,et al.PIOS(Patras Immunotherapy Score)score is associated with best overall response,progression-free survival,and post-immunotherapy overall survival in patients with advanced non-small-cell lung cancer(NSCLC)treated with anti-program cell death-1(PD-1)inhibitors[J].Cancers(Basel),2020,12(5):1257.
11 Dumenil C,Massiani MA,Dumoulin J,et al.Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab[J].PLoS One,2018,13(4):0195945.
12 Kichenadasse G,Miners JO,Mangoni AA,et al.Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer[J].JAMA Oncol,2020,6(4):512-518.
13 Cortellini A,Ricciuti B,Tiseo M,et al.Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥50%:a multicenter study with external validation[J].J Immunother Cancer,2020,8(2):001403.
14 Ichihara E,Harada D,Inoue K,et al.The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer[J].Lung Cancer,2020,139:140-145.
15 Wang F,Zhou L,Chen N,et al.The effect of pretreatment BMI on the prognosis and serum immune cells in advanced LSCC patients who received ICI therapy[J].Medicine(Baltimore),2021,100(8):24664.
16 Richtig G,Hoeller C,Wolf M,et al.Body mass index may predict the response to ipilimumab in metastatic melanoma:An observational multi-centre study[J].PLoS One,2018,13(10):e0204729.
17 Naik GS,Waikar SS,Johnson AEW,et al.Complex inter-relationship of body mass index,gender and serum creatinine on survival:exploring the obesity paradox in melanoma patients treated with checkpoint inhibition[J].J Immunother Cancer,2019,7(1):89.
18 Mcquade JL,Daniel CR,Hess KR,et al.Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy,immunotherapy,or chemotherapy:a retrospective,multicohort analysis[J].Lancet Oncol,2018,19(3):310-322.
19 Donnelly D,Bajaj S,Yu J,et al.The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients[J].J Immunother Cancer,2019,7(1):222.
20 Rutkowski P,Indini A,De Luca M,et al.Body mass index(BMI)and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy:a multicenter international retrospective study[J].J Immunother Cancer,2020,8(2):001117.
21 Xue Y,Gao S,Gou J,et al.Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors:preclinical and clinical studies and mechanism of action[J].Expert Opin Drug Deliv,2021,18(2):187-203.
22 Hosseini A,Gharibi T,Marofi F,et al.CTLA-4:From mechanism to autoimmune therapy[J].Int Immunopharmacol,2020,80:106221.
23 Skowron F,Berard F,Balme B,et al.Role of obesity on the thickness of primary cutaneous melanoma[J].J Eur Acad Dermatol Venereol,2015,29(2):262-269.
24 Brandon EL,Gu JW,Cantwell L,et al.Obesity promotes melanoma tumor growth:role of leptin[J].Cancer Biol Ther,2009,8(19):1871-1879.
25 Goebell PJ,Muller L,Hubner A,et al.Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment-Analyses from the German clinical RCC-Registry[J].Urol Oncol,2018,36(10):471-479.
26 Motzer RJ,Russo P,Haas N,et al.Adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma:final overall survival analysis of the phase 3 PROTECT trial[J].Eur Urol,2021,79(3):334-338.
27 De Giorgi U,Procopio G,Giannarelli D,et al.Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab[J].Clin Cancer Res,2019,25(13):3839-3846.
28 Labadie BW,Liu P,Bao R,et al.BMI,irAE,and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma[J].J Transl Med,2019,17(1):386.
29 Sanchez A,Furberg H,Kuo F,et al.Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma:a cohort study[J].Lancet Oncol,2020,21(2):283-293.
30 Boi SK,Orlandella RM,Gibson JT,et al.Obesity diminishes response to PD-1-based immunotherapies in renal cancer[J].J Immunother Cancer,2020,8(2):e000725.
31 Fan X,Wang D,Zhang W,et al.Inflammatory markers predict survival in patients with advanced gastric and colorectal cancers receiving anti-PD-1 therapy[J].Front Cell Dev Biol,2021,9:638312.
32 Bally AP,Austin JW,Boss JM.Genetic and epigenetic regulation of PD-1 expression[J].J Immunol,2016,196(6):2431-2437.
33 Bu LL,Yu GT,Wu L,et al.STAT3 induces immunosuppression by upregulating PD-1/PD-L1 in HNSCC[J].J Dent Res,2017,96(9):1027-1034.
34 Rasouli N,Kern PA.Adipocytokines and the metabolic complications of obesity[J].J Clin Endocrinol Metab,2008,93(11 Suppl 1):64-73.
35 Wang Z,Aguilar EG,Luna JI,et al.Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade[J].Nat Med,2019,25(1):141-151.

[1]	吴芳芳, 郑桐森. 胆道恶性肿瘤辅助治疗的研究现状及展望[J]. 实用肿瘤学杂志, 2022, 36(2): 156-161.
[2]	王艳平, 邱琳, 武萌, 飒日娜. 2016年陕西省恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2022, 36(1): 1-6.
[3]	刘金爽, 张文静, 黎清炜, 李志伟. 免疫检查点抑制剂的联合治疗在胰腺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 49-53.
[4]	杨开炎, 韦永昌, 杨秋云, 唐凤珠. 鼻咽癌的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 542-546.
[5]	于园园, 孟千皓, 王广雨. 胃癌免疫治疗困境与未来方向[J]. 实用肿瘤学杂志, 2021, 35(6): 552-556.
[6]	刘菲, 隋红. 基于肿瘤免疫微环境的肝癌分子分型研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 557-561.
[7]	李响, 胡洋, 张清媛. 肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 568-571.
[8]	李娜, 邓茜, 蒋建军. NF-κB信号通路在恶性肿瘤化疗耐药中的作用[J]. 实用肿瘤学杂志, 2021, 35(6): 580-584.
[9]	符艳, 颜李丽, 王春雨, 符芳敏, 董华. 2010—2016年琼海市恶性肿瘤流行情况分析[J]. 实用肿瘤学杂志, 2021, 35(5): 396-401.
[10]	金升烨, 庞达. 溶瘤病毒诱导肿瘤凋亡及激活抗肿瘤免疫机制的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 462-467.
[11]	范琳, 田霖丽, 刘鸣. 单细胞测序技术在头颈部恶性肿瘤中的研究与发展[J]. 实用肿瘤学杂志, 2021, 35(5): 472-475.
[12]	董华, 王定彬, 华婧, 范康琼, 马楠楠, 王兴任. 2016年海南省肿瘤登记地区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2021, 35(4): 344-350.
[13]	陈莉莉, 刘玉琴, 丁高恒, 苏海翔. 甘肃省恶性肿瘤流行情况及防控现状[J]. 实用肿瘤学杂志, 2021, 35(3): 254-257.
[14]	马明瑞, 连洁, 刘超, 娄长杰, 张艳桥. 消化系统肿瘤“免疫治疗前移”的探索[J]. 实用肿瘤学杂志, 2021, 35(3): 258-262.
[15]	国昊楠, 秦韬. MYO10与恶性肿瘤的研究进展[J]. 实用肿瘤学杂志, 2021, 35(3): 273-276.